Novel 2′‐substituted, 3′‐deoxy‐phosphatidyl‐myo‐inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3‐kinase/Akt pathway

DOI Web Site Web Site 被引用文献2件

抄録

<jats:title>Summary</jats:title><jats:p>Activation of the phosphoinositide 3‐kinase (PI3‐K)/Akt signalling pathway has been linked with resistance to chemotherapeutic drugs, and its down‐regulation, by means of pharmacological inhibitors of PI3‐K, considerably lowers resistance to various types of therapy in cell lines derived from solid tumours. Recently, a new class of Akt inhibitors, referred to as phosphatidylinositol ether lipids (PIAs), have been synthesized. We tested whether two new PIAs could lower the sensitivity threshold to chemotherapeutic drugs of human leukaemia cell lines with an activated PI3‐K/Akt network. We used HL60AR (for apoptosis resistant), K562 and U937 cells. The two pharmacological inhibitors, used at 5 <jats:italic>μ</jats:italic>mol/l, down‐regulated Akt kinase activity and phosphorylation. Neither of the two chemicals affected the activity of other signalling proteins in the Akt pathway, such as phosphoinositide‐dependent protein kinase‐1 or PTEN. When employed at 5 <jats:italic>μ</jats:italic>mol/l, the Akt inhibitors markedly reduced the resistance of the leukaemic cell lines to etoposide or cytarabine. Remarkably, a 5 <jats:italic>μ</jats:italic>mol/l concentration of the inhibitors did not negatively affect the survival rate of human cord blood CD34<jats:sup>+</jats:sup> cells. Overall, our results indicate that new selective Akt pharmacological inhibitors might be used in the future for overcoming Akt‐mediated resistance to therapeutic treatments of acute leukaemia cells.</jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ